Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.14 USD
Change Today +0.04 / 1.90%
Volume 1.6M
ATRS On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/14 - $3.20
52 Week Low
09/30/14 - $1.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Vibex self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle. Its transdermal gel products comprise Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company also offers OTREXUP, an injection for subcutaneous use indicated for adults with severe active RA, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis, as well as Vibex auto injectors. In addition, it is developing Vibex QS T for testosterone replacement therapy for men who have testosterone deficiency; Vibex QS M with an undisclosed drug for treatment of a CNS indication; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Meda Pharmaceuticals, Inc.; Pfizer Inc; Population Council; and LEO Pharma, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

93 Employees
Last Reported Date: 03/12/15
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $292.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $43.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $391.1K
Head of Human Resources, Senior Vice Presiden...
Total Annual Compensation: $205.2K
Compensation as of Fiscal Year 2014.

antares pharma inc (ATRS) Key Developments

Antares Pharma Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Antares Pharma Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $8.35 million compared to $5.20 million a year ago. Operating loss was $6.74 million compared to operating loss of $8.81 million a year ago. Net loss was $6.79 million or $0.05 per basic and diluted share compared to $8.80 million or $0.07 per basic and diluted share a year ago. Product sales, which represent sales of proprietary products, devices and device components to customers, were $4.6 million compared to $1.8 million last year. The increase in product sales was primarily driven by higher sales of OTREXUP. Development revenues represent amounts earned under arrangement with partners in which the company develop new products on their behalf. Frequently, the company receive payments from partners that are initially deferred and recognized as revenue over a development period or upon completion of defined deliverables. 2015 development revenue was $2.4 million compared to $1.4 million in 2014, representing a 68% growth. Licensing revenues represent the amounts recognized from upfront or milestone payments received from partners that are initially deferred and then recognized over the life of the agreement. Licensing revenue was $900,000 for both 2015 and 2014. 2015 royalty Revenue was $500,000 compared to $1 million in 2014. The decrease in royalties is primarily due to the decision taken by Teva in April 2014 to recall the drug product, Tev-Tropin, and hence, temporarily eliminate all revenues related to Tev-Tropin in the U.S.

Antares Pharma Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 04:20 PM

Antares Pharma Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 04:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Eamonn P. Hobbs, Chief Executive Officer, President and Director.

Antares Pharma Seeks Acquisitons

Antares Pharma Inc. (NasdaqCM:ATRS) has priced an underwritten public offering of 20 million shares of its common stock. The company expects to use the net proceeds of the offering for general corporate purposes, including business development, in-licensing and acquisitions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.14 USD +0.04

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $1.68 USD -0.15
Cerus Corp $4.46 USD -0.09
Pluristem Therapeutics Inc $2.85 USD -0.01
STAAR Surgical Co $9.02 USD -0.06
SurModics Inc $24.90 USD -1.04
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.3x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at